The Prognostic Impact of Psychotropic Drugs in Intentional Drug Overdose

 

 Buy Article Permissions and Reprints

Abstract

Introduction: Psychotropic drugs belong to the drugs most frequently involved in intentional drug overdose (IDO). Few studies have explored their prognostic impact during hospitalisation for IDO.

Methods: In order to assess which types of psychotropic drugs ingested during IDOs were associated with an increased morbidity, a cohort study included 1 974 patients consecutively hospitalised for IDO. IDOs were categorised as serious if associated with one of the following criteria: death, hospitalisation longer than 48 h, respiratory support, vasopressive drugs, cardiac massage or dialysis.

Results: Nearly all the patients ingested psychotropic medications during the IDO (88.4%), most often benzodiazepines (71.6%). Serious IDO was associated with tricyclics (OR 5.7; 95% CI 3.3–9.8), lithium (OR 4.3; 95% CI 1.6–11.6), carbamates (OR 2.7; 95% CI 1.8–4), anticonvulsants (OR 2.4: 95% CI 1.4–4.3), first-generation antipsychotics (OR 2.4; 95% CI 1.7–3.5) or selective serotonin reuptake inhibitors (SSRIs) (OR 1.6; 95% CI 1.1–2.3).

Discussion: Some drugs may be dangerous because of low toxic doses; hence, prescriptions of short duration may be recommended. Moreover, for safety reasons, prescribers may prefer SSRIs to tricyclics and benzodiazepines to carbamates or phenothiazines.

References

• 1 Baca-Garcia E, Diaz-Sastre C, Saiz-Ruiz J. et al . How safe are psychiatric medications after a voluntary overdose?.  Eur Psychiatry. 2002;  17 466-470
  CrossrefPubMedGoogle Scholar
• 2 Buckley NA, Dawson AH, Whyte IM. et al . An analysis of age and gender influences on the relative risk for suicide and psychotropic drug self-poisoning.  Acta Psychiatr Scand. 1996;  93 168-171
  CrossrefPubMedGoogle Scholar
• 3 Caisse nationale de l’Assurance Maladie .Dossier MEDIC’Assurance Maladie 2006. In: Caisse nationale de l’Assurance Maladie. Paris 2007
  Google Scholar
• 4 Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents.  Int J Neuropsychopharmacol. 2000;  3 51-54
  CrossrefPubMedGoogle Scholar
• 5 Haro L de, Roelandt J, Pommier P. et al . Aetiologies of lithium overdose: 10-year experience of Marseille poison centre.  Ann Fr Anesth Reanim. 2003;  22 514-519
  PubMedGoogle Scholar
• 6 Doshi A, Boudreaux ED, Wang N. et al . National study of US emergency department visits for attempted suicide and self-inflicted injury, 1997–2001.  Ann Emerg Med. 2005;  46 369-375
  CrossrefPubMedGoogle Scholar
• 7 European Pharmaceutical Marketing Research Association (EphMRA) . The Anatomical Classification of Pharmaceutical Products. 2006;  http://www.ephmra.org/main.asp
  PubMed
• 8 Gunnell D, Hawton K, Murray V. et al . Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified?.  J Epidemiol Community Health. 1997;  51 175-179
  CrossrefPubMedGoogle Scholar
• 9 Hawton K, Simkin S, Deeks J. et al . UK legislation on analgesic packs: before and after study of long term effect on poisonings.  BMJ. 2004;  329 1076
  CrossrefPubMedGoogle Scholar
• 10 Hawton K, Townsend E, Deeks J. et al . Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study.  BMJ. 2001;  322 1203-1207
  CrossrefPubMedGoogle Scholar
• 11 Lamprecht HC, Pakrasi S, Gash A. et al . Deliberate self-harm in older people revisited.  Int J Geriatr Psychiatry. 2005;  20 1090-1096
  CrossrefPubMedGoogle Scholar
• 12 Litovitz TL, Klein-Schwartz W, White S. et al . 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.  Am J Emerg Med. 2001;  19 337-395
  CrossrefPubMedGoogle Scholar
• 13 Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care.  Br J Gen Pract. 2000;  50 366-370
  PubMedGoogle Scholar
• 14 Matsika MD, Tournier M, Lagnaoui R. et al . Comparison of patient questionnaires and plasma assays in intentional drug overdoses.  Basic Clin Pharmacol Toxicol. 2004;  95 31-37
  PubMedGoogle Scholar
• 15 Moore N, Briffaut C, Noblet C. et al . Indirect drug-related costs.  Lancet. 1995;  345 588-589
  PubMedGoogle Scholar
• 16 Novack V, Jotkowitz A, Delgado J. et al . General characteristics of hospitalized patients after deliberate self-poisoning and risk factors for intensive care admission.  Eur J Intern Med. 2006;  17 485-489
  PubMedGoogle Scholar
• 17 Olfson M, Gameroff MJ, Marcus SC. et al . National trends in hospitalization of youth with intentional self-inflicted injuries.  Am J Psychiatry. 2005;  162 1328-1335
  CrossrefPubMedGoogle Scholar
• 18 Otsubo T, Akimoto Y, Yamada H. et al . A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.  Pharmacopsychiatry. 2005;  38 30-35
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Ott P, Dalhoff K, Hansen PB. et al . Consumption, overdose and death from analgesics during a period of over-the-counter availability of paracetamol in Denmark.  J Intern Med. 1990;  227 423-428
  CrossrefPubMedGoogle Scholar
• 20 Ruths FA, Tobiansky RI, Blanchard M. Deliberate self-harm (DSH) among older people: a retrospective study in Barnet, North London.  Int J Geriatr Psychiatry. 2005;  20 106-112
  CrossrefPubMedGoogle Scholar
• 21 Shah R, Uren Z, Baker A. et al . Deaths from antidepressants in England and Wales 1993–1997: analysis of a new national database.  Psychol Med. 2001;  31 1203-1210
  PubMedGoogle Scholar
• 22 Staikowsky F, Theil F, Mercadier P. et al . Change in profile of acute self drug-poisonings over a 10-year period.  Hum Exp Toxicol. 2004;  23 507-511
  CrossrefPubMedGoogle Scholar
• 23 Tournier M, Grolleau A, Cougnard A. et al . Factors associated with choice of psychotropic drugs used for intentional drug overdose.  Eur Arch Psychiatry Clin Neurosci. , 2008
  PubMedGoogle Scholar
• 24 Tournier M, Molimard M, Abouelfath A. et al . Prognostic impact of psychoactive substances use during hospitalization for intentional drug overdose.  Acta Psychiatr Scand. 2005;  112 134-140
  CrossrefPubMedGoogle Scholar
• 25 Tournier M, Molimard M, Abouelfath A. et al . Accuracy of self-report and toxicological assays to detect substance misuse disorders in parasuicide patients.  Acta Psychiatr Scand. 2003;  108 410-418
  CrossrefPubMedGoogle Scholar
• 26 Tournier M, Molimard M, Cougnard A. et al . Psychiatric disorders and their comorbidity in subjects with parasuicide by intentional drug overdose: prevalence and gender differences.  Psychiatry Res. 2005;  136 93-100
  CrossrefPubMedGoogle Scholar
• 27 Tournier M, Molimard M, Titier K. et al . Accuracy of information on substance use recorded in medical charts of patients with intentional drug overdose.  Psychiatry Res. 2007;  152 73-79
  CrossrefPubMedGoogle Scholar
• 28 Ulrich S, Hiemke C, Laux G. et al . Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence.  Pharmacopsychiatry. 2007;  40 121-127
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 WHO Collaborating Centre for Drug Statistics Methodology .About the ATC/DDD system. In: Norwegian Institute of Public Health. Oslo, Norway 2007
  Google Scholar
• 30 Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation.  Am J Health Syst Pharm. 2008;  65 1029-1038
  CrossrefPubMedGoogle Scholar

Correspondence

M. TournierMD, PhD 

Hôpital Charles Perrens

121 rue de la Béchade

33076 Bordeaux cedex

France

Phone: +33/5/5656 17 71

Fax: +33/5/5656 35 46

Email: mtournier@ch-perrens.fr